Panaccione R, Feagan BG, Afzali A, Rubin DT, et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double Lancet 2025 Jul 17:S0140-6736(25)00681-6. doi: 10.1016/S0140-6736(25)00681.
PMID: 40684778